Back to search

Article

Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta

2025-05-27

Abstract excerpt

Increased risk of fracture is a hallmark feature in the skeletal disorder Osteogenesis Imperfecta (OI). One therapy in clinical trials for OI is an antibody that neutralizes sclerostin (a Wnt signaling inhibitor) that is already FDA approved for patients with osteoporosis. In addition to increasing bone mass and lowering incident fractures in patients with osteoporosis, anti-sclerostin antibody increased bone mass...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
93f5feca-f6a9-5fc9-80dd-8b9b4cb8d653
DOI
10.1101/2025.05.27.656429
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis ImperfectaDOI 10.1101/2025.05.27.656429
Select a neighboring publication to make it the new centre.